Clinical Edge Journal Scan

Evidence supporting initiation of CRC screening before 50 years of age in women


 

Key clinical point: Colorectal cancer (CRC) screening before 50 years of age was associated with a reduced risk for CRC among US women, including CRC diagnosis before 55 years of age.

Major finding: Compared with no endoscopy, initiating endoscopy at the age of <45 (adjusted hazard ratio [aHR] 0.37; 95% CI 0.26-0.53), 45-49 (aHR 0.43; 95% CI 0.29-0.62), 50-54 (aHR 0.47; 95% CI 0.35-0.62), and ≥55 (aHR 0.46; 95% CI 0.30-0.69) years was associated with a significantly lower CRC risk, with initiating endoscopy before 50 years of age being associated with a decreased risk for CRC diagnosis before 55 years of age (<45 years: aHR 0.45, 95% CI 0.29-0.70; 45-49 years: aHR 0.43, 95% CI, 0.24-0.76).

Study details: This prospective cohort study enrolled 111,801 female health professionals aged 26-46 years with no history of cancer from the Nurses’ Health Study II.

Disclosures: The study was supported by the US National Institutes of Health (NIH). Some authors reported serving as consultants for or receiving research grants or personal fees from various organizations, including NIH.

Source: Ma W et al. Age at initiation of lower gastrointestinal endoscopy and colorectal cancer risk among US women. JAMA Oncol. 2022 (May 5). Doi: 10.1001/jamaoncol.2022.0883

Recommended Reading

CRC screening: Blood test accuracy compared to colonoscopy
MDedge Hematology and Oncology
Alarming increase in esophageal cancer in middle-aged adults
MDedge Hematology and Oncology
Metastatic CRC: Phase 3 supports extension of sequential treatment over combination
MDedge Hematology and Oncology
KEYNOTE-177 delivers final results with pembrolizumab vs chemotherapy for MSI-H or dMMR mCRC
MDedge Hematology and Oncology
Unresectable mCRC: Final survival outcomes with first-line trifluridine/tipiracil plus bevacizumab in TASCO1
MDedge Hematology and Oncology
Proton pump inhibitors curb capecitabine efficacy in stage II-III CRC
MDedge Hematology and Oncology
Proton pump inhibitors curb capecitabine efficacy in stage II-III CRC
MDedge Hematology and Oncology
Survival after CRS-HIPEC in synchronous vs metachronous peritoneal metastasis of CRC
MDedge Hematology and Oncology
Can proximal serrated polyp detection rate serve as an indicator for interval post-colonoscopy CRC?
MDedge Hematology and Oncology
Can proximal serrated polyp detection rate serve as an indicator for interval post-colonoscopy CRC?
MDedge Hematology and Oncology